FLUOPTICS was honoured by the Présences revue of Grenoble CCI
Last November FLUOPTICS receives the market authorization from FDA for FLUOBEAM® to detect parathyroid tissue in real time during surgery.
It is a recognition of the performance of the FLUOBEAM® and for the development of fluorescence imaging.
Today, we are highlighted in the Presences revue of the Grenoble CCI for this market authorization.
For more information, please click on the link Présences_CCI de Grenoble.